Navigation Links
Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Date:7/2/2008

them for signs of anti-tumor activity. We look forward to sharing more data from this study as patient treatment and follow-up progress."

The primary objective of the multi-center Phase II clinical trial is to assess overall tumor response rate. Secondary objectives include measuring time to tumor progression, duration of response, overall patient survival and safety parameters. All tumor responses in the trial are being evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Patients may continue to receive bavituximab as solo therapy after completion of chemotherapy as long as the cancer does not progress and side effects are acceptable. The trial is being conducted in the Republic of Georgia according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

According to the RECIST criteria, patients are categorized as having "stable disease" ("SD") if they have less than a 20% increase to a 30% reduction in the sum of the target lesions, and they are categorized as having a "partial response" ("PR") if they experience greater than a 30% reduction in the sum of target lesions. In addition, to be assigned a status of SD or PR, patients cannot have the appearance of any new lesions.

According to the World Health Organization, breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease in the U.S. alone.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to h
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
2. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
3. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
4. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
5. Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
6. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
7. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
8. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
9. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FLINT, Mich. , Dec. 24, 2014  Diplomat ... largest independent specialty pharmacy, is proud to announce ... and quality at Diplomat, will take office as the ... 2015. The formal induction ceremony will take place Feb. ... which will be held at the Renaissance Center in ...
(Date:12/24/2014)... LONDON , December 24, 2014 ... grow at an average rate of 8.1%. The US ... Hip, knee and spine surgeries are the common orthopedic ... they have a lower penetration. Increased number of product ... composites. Non-metallic orthopedic devices have gained popularity in the ...
(Date:12/24/2014)... Dec. 23, 2014 Echo Therapeutics, Inc. ... company focused on skin permeation, continuous glucose monitoring ... W. Hollander has been appointed Chief Executive ... more than 20 years of experience in the ... most recently served as Vice President, Business Development, ...
Breaking Medicine Technology:Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... N.C., Nov. 10, 2011 BioDelivery Sciences International, ... it has initiated a confirmatory pharmacokinetic study of ... patented BioErodible MucoAdhesive (BEMA) drug delivery technology.   ... The study, BNX-102, will be used to select ...
... Nov. 10, 2011 /PRNewswire-Asia/ -- Korean Ministry of Health ... Development Institute (President Ko, Kyung-hwa) have announced that it ... from eight countries by the end of November through ... a brand to promote South Korea,s advanced medical technology ...
Cached Medicine Technology:BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone 2BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone 3BioDelivery Sciences Initiates Confirmatory Pharmacokinetic Study of BEMA Buprenorphine/Naloxone Compared to Suboxone 42011 Korea's Medical Charity Program offers care for 31 int'l child patients 2
(Date:12/25/2014)... December 26, 2014 The ... combines beauty, strength and durability. Today, the business ... which is valid until Jan. 30, 2015. , ... of traditional hardwood. BambooFlooringChina.com is a well-known brand ... consumers worldwide to find a reliable bamboo flooring ...
(Date:12/25/2014)... “Every three months the trends for ... evening dress will be one of the hottest styles in ... says. Today, the company releases 26 A-line sweetheart evening dresses, ... off. , “We are trying our best to help ... latest designs. Along with affordable prices, we provide discounted delivery ...
(Date:12/25/2014)... 25, 2014 Recently, BellasDress ... all its wedding dresses. BellasDress has chosen their best-selling ... gift choices for the holiday season. , Now, ... suitable wedding gowns here at discount prices. The business ... at its website. , “All our elegant ...
(Date:12/25/2014)... updated its blog to provide professional shopping tips on wedding and ... LunaDress.co.uk come with big discounts, up to 80 percent off. , ... to be a most exciting memory and can show off a ... a wedding. On the updated fashion blog, ladies can now find ... day . , Going out with friends to a party is ...
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... , ... A. Abelson says proposed curbs address an illusion instead of the real problem — ... ... personal injury lawyer in Maryland and Washington, DC, says proposed limits on damage awards ...
... benefit actually stems from overall healthier lifestyle remains unclear, , ... for infants are numerous and well-known, but researchers are finding ... mom,s health as well. , In fact, the latest study ... amounts of abdominal fat, even decades later. , The study, ...
... ... ... , ... DAYTON, N.J. , March 5 Mincing Overseas Spice Company of ...
... ... Link is Citizen Preparedness , ... Sacramento, CA (PRWEB) March 5, 2010 -- A majority of Californians have ... not done enough to make their homes safer and guard their personal finances in ...
... ... ... ... ...
... stem from the devices or patient error, FDA panel says ... insulin pumps used to treat diabetes should try to supply ... problems with the devices, an advisory panel to the U.S. ... devices are required to report when a device malfunctions or ...
Cached Medicine News:Health News:Congressional Concession On Medical Malpractice Awards Will Not Lower Health Care Costs And Will Hurt Patients' Rights, Washington, DC Attorney Says 2Health News:Congressional Concession On Medical Malpractice Awards Will Not Lower Health Care Costs And Will Hurt Patients' Rights, Washington, DC Attorney Says 3Health News:Breast-Feeding Helps Mom Stay Slimmer Later in Life 2Health News:Breast-Feeding Helps Mom Stay Slimmer Later in Life 3Health News:Mincing Overseas Spice Company Voluntarily Recalls Two Lots of Black Pepper 2Health News:Study Reveals Californians Must Increase Earthquake Preparedness; Less Than 20 Percent Have Prepared Their Homes; Only 40 Percent Have Sufficient Water 2Health News:Study Reveals Californians Must Increase Earthquake Preparedness; Less Than 20 Percent Have Prepared Their Homes; Only 40 Percent Have Sufficient Water 3Health News:Study Reveals Californians Must Increase Earthquake Preparedness; Less Than 20 Percent Have Prepared Their Homes; Only 40 Percent Have Sufficient Water 4Health News:Study Reveals Californians Must Increase Earthquake Preparedness; Less Than 20 Percent Have Prepared Their Homes; Only 40 Percent Have Sufficient Water 5Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 2Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 3Health News:More Info Needed on Problems With Insulin Pumps 2Health News:More Info Needed on Problems With Insulin Pumps 3
Unique criss-cross strapping. The MSV-10 is our most popular model. Extra wide Velcro ensures a wide variety of adjustments and easy closing....
Our 'flex' removes the apron weight from the shoulders while providing back support. Unlike other elastic backs, ours does not wrinkle up, making cleaning easier....
... fully featured Peripheral Nerve Stimulator and Locator. ... blocks during surgery or intensive care procedures, ... , ,The constant current NS232, NS252, ... that can be programmed. ,Hand-held, battery operated, ...
... New Innervator NS232 is a basic Peripheral ... stimulation patterns for nerve location during regional ... emergency room. ,The constant current NS232, ... PNS that can be programmed. ,Hand-held, battery ...
Medicine Products: